Summary of the Study Sample Clauses

Summary of the Study. [Drafting note: The 250 word (max) “Study Summary” from Application Form to be included]
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Summary of the Study. [Drafting note: The 250 word (max) “Study Summary” from Application Form to be included] [Drafting note: Recipient to complete. Clearly outline the role of each on the Study Participant and approved subcontractors for Major Subcontract Work.] The Recipient will deliver the following outputs from the Study: (a) A finalised [Feasibility or Engineering – select as appropriate] Study Report as described at Schedule 1, Item 4.7; and (b) Other Knowledge Sharing Deliverables as set out in item 4.6 of Schedule 1 (Knowledge Sharing Plan).
Sample 1
Summary of the Study. This section provides a summary of the study, the main goal of which is to determine parental perspectives of school-aged children with DS towards inclusive education. The qualitative research adopted case study and phenomenology designs to address three research questions: (1) What are the attitudes of parents of school-aged children with Down syndrome towards the inclusion of their children in mainstream schools in Petropavlovsk? (2) What factors influence parental attitudes towards inclusive education? (3) How do parents advocate for the rights of the children with Down syndrome to be included in mainstream schools in Petropavlovsk? The study has shown that parents of school-aged children who have the diagnosis of DS and live in Petropavlovsk have a positive attitude towards inclusive education; nevertheless, the majority of respondents do not regard the mainstream school as a good setting for their children with special needs. Although many parents indicated the benefits that regular schools may provide, they hold a negative attitude towards the inclusion of their children with DS in a mainstream setting. The findings of this study suggest that a child's problems with health, a negative attitude towards children with DS, PMPC, a challenging curriculum, lack of teaching assistants and underqualified teachers in mainstream schools are the main barriers on the way to inclusive education. The results of this research support the idea that such factors as parental level of education, socio-economic status, personal experience, and expertise in the area of inclusive education have a significant impact on the perspectives, opinions, and behavior of parents. Another significant finding to emerge from this study is that the birth of a child with DS influences the families in different ways. Parental life can be associated with the 'battlefield' where mothers have to fight for the rights of their children with special needs.
Sample 1
Summary of the Study. [Drafting note: The 250 word (max) “Study Summary” from Application Form to be included] [Drafting note: Recipient to complete. Clearly outline the role of each on the Study Participant and approved subcontractors for Major Subcontract Work.] Under this Agreement, the following Outputs are to be provided A finalised [Feasibility or Engineering – select as appropriate] Study Report as described at Schedule 1, Item 4.6: Other knowledge Sharing Deliverables as set out in item 4 of Schedule 1 (Knowledge Sharing Plan) The Study will deliver the following Outcomes: Enable a decision by the Applicant to either proceed to fund implementation of the studied Project or proceed to a more detailed engineering study of the studied Project; Inform industry of the barriers to implementation of the studied Project and potential solutions to these barriers; Accelerate uptake of similar projects across industry; and Enable accelerated transformational improvement in industrial renewable energy and/or energy efficiency and greenhouse gas emissions compared to baseline or business as usual. The Study will deliver the following Outcomes: Enable a Final Investment Decision regarding whether proceed to fund implementation of the studied Project; Inform industry of the barriers to implementation of the studied Project and potential solutions to these barriers; Accelerate uptake of similar projects across industry; and Enable accelerated transformational improvement in industrial renewable energy and/or energy efficiency and greenhouse gas emissions compared to baseline or business as usual. Milestones (clause 2) The Recipient must achieve the following Milestones and provide the Milestone Deliverables and any Reports in a form and substance satisfactory to ARENA, by the Completion date of the relevant Milestone.
Sample 1
Summary of the Study. This study has been subdivided into five chapters each as described below;
Sample 1
Summary of the Study. The aim of the study was to explore the way the Dutch Green Deals and WRAP agreements, in particular the CPGD and the CC function. The data was collected through theme interviews with eight experts working in Dutch and UK govern- ments, WRAP and the founding organizations of the CPGD. The research find- ings revealed how these VEAs function and how their efficiency is measured. This was achieved through in-depth exploration of the three main categories: de- velopment, implementation and performance and added value. The aim of this section is to highlight the key research findings in relation to the main research questions of the study. According to the research findings the Green Deals and WRAP agree- ments were initiated to tackle environmental issues through public-private co- operation. The Dutch Green Deals are voluntary agreements between the Dutch national government and various stakeholders. In fact, the government is one of the participants in the Green Deals. On the contrary, WRAP agreements are funded by the UK government and organized by WRAP. Thus, the government does not participate directly in the agreements.
Sample 1
Summary of the Study. [Drafting note: The 250 word (max) “Study Summary” from Application Form to be included] [Drafting note: Recipient to complete. Clearly outline the role of each on the Study Participant and approved subcontractors for Major Subcontract Work.] [Consultant] [Study Participant/ approved subcontractor for Major Subcontract Work] [Recipient] has engaged Consultant XXX to assist in delivering the Study report.
Sample 1
AutoNDA by SimpleDocs
Summary of the Study. The purpose of this study was to understand teachers’ perceptions of primary and secondary trauma based on their emotional, professional, and relational impacts. It also aimed to examine what forms of trauma educators encounter within their school sites. The design used in this study was a mixed methods study. Data was collected using an online survey comprised of multiple-choice, Likert-scale, and open-ended questions. The research sample focused on teachers who are currently in the classroom and are supporting students who have experienced trauma. The study examined the following research questions:
Sample 1

Related to Summary of the Study

  • Project Summary The main objective of the LIFE GAIA Sense project is to demonstrate gaiasense, an innovative “Smart Farming” (SF) solution that aims at reducing the consumption of natural resources, as a way to protect the environment and support Circular Economy (CE) models. More specifically, this project will launch 18 demonstrators across Greece, Spain and Portugal covering 9 crops (olives, peaches, cotton, pistachio, potatoes, table tomatoes, industrial tomatoes, grapes, kiwi) in various terrain and microclimatic conditions. They will demonstrate an innovative method, based on high-end technology, which is suitable for being replicated and will be accessible and affordable to Farmers either as individuals or collectively through Agricultural Cooperatives. Moreover, LIFE GAIA Sense aims to promote resource efficiency practices in SMEs of the agricultural sector and eventually, contribute to the implementation of the Roadmap to a Resource Efficient Europe. This project will demonstrate a method on how the farmer will be able to decide either to use or avoid inputs (irrigation, fertilizers, pesticides etc.) in a most efficient way, without risking the annual production. The focus is on the resource consumption reduction side of CE, and the results will be both qualitatively and quantitatively, considering the resources’ efficiency in agricultural sector.

  • Conduct of the Study 3.1 Syndax shall act as the sponsor of the Study and shall hold the IND relating to the Study. Merck acknowledges that Syndax intends to file a separate IND covering the clinical evaluation of the Syndax Compound to treat melanoma and lung-related indications and to perform the Study under such IND. This separate IND will not be a combination IND. If a Regulatory Authority requests a separate combination IND for the Study the Parties will meet and mutually agree on an approach to address such requirement. 3.2 Syndax shall ensure that the Study is performed in accordance with this Agreement, the Protocol and all Applicable Law, including GCP. 3.3 Syndax shall ensure that all directions from any Regulatory Authority and/or ethics committee with jurisdiction over the Study are followed. Further, Syndax shall ensure that all necessary Regulatory Approvals from any Regulatory Authority and/or ethics committee with jurisdiction over the Study are obtained prior to initiating performance of the Study. Syndax shall participate in and lead all discussions with any Regulatory Authority regarding the Study, provided, however, that Merck shall have the right (but no obligation) to participate in any discussions with a Regulatory Authority regarding matters related to the Merck Compound. Notwithstanding anything to the contrary in this Agreement, neither Party shall have any right to access the other Party’s CMC data with respect to its Compound. Merck will authorize FDA and other applicable Regulatory Authorities to cross-reference the appropriate Merck Compound CTA to provide data access to Syndax sufficient to support conduct of the Study, which authorization will take the form of a cross-reference letter or similar communication to the applicable Regulatory Authority to effectuate a “right of reference” (as defined in US FDA 21 CFR 314.3(b)), or similar “right of reference” as defined in applicable regulations in the relevant part of the Territory. If an appropriate Merck Compound CTA is not available in a given country, Merck will file its CMC data as appropriate and grant right of reference to such CMC data; provided, however, that Syndax shall have no right to directly access the CMC data. 3.4 Syndax shall maintain reports and all related documentation relating to the Study in good scientific manner and in compliance with Applicable Law. Each Party shall provide to the other all Study information and documentation (excluding information and documentation relating to the Sample Testing other than the Sample Testing Results themselves) reasonably requested by such other Party to enable it to (i) comply with any of its legal and regulatory obligations, or any request by any Regulatory Authority, in each case, to the extent related to the Study or such Party’s Compound, or (ii) conduct the Sample Testing. 3.5 Each Party shall provide to the other Party copies of all Clinical Data, in electronic form or other mutually agreeable alternate form, and on the timelines specified in the Data Sharing and Sample Testing Schedule (if applicable) or upon mutually agreeable timelines. Syndax shall ensure that all patient authorizations and consents required under HIPAA, the EU Data Protection Directive, GCP or any other Applicable Law in connection with the Study permit such sharing of Clinical Data with Merck. 3.6 Syndax shall provide Samples to Merck as specified in the Protocol or as agreed to by the Joint Development Committee. Each Party shall use the Samples only for the Sample Testing and each Party shall be responsible for conducting the Sample Testing related to its own Compound. Merck shall own all data arising from the Sample Testing conducted by or on behalf of Merck. Merck shall provide to Syndax the Sample Testing Results for the Sample Testing conducted by or on behalf of Merck, in electronic form or other mutually agreeable alternate form, and on the timelines specified in the Data Sharing and Sample Testing Schedule or other mutually agreed timelines. Likewise, Syndax shall own all data arising from the Sample Testing conducted by or on behalf of Syndax. Syndax shall provide to Merck the Sample Testing Results for the Sample Testing conducted by or on behalf of Syndax, in electronic form or other mutually agreeable alternate form, and on the timelines specified in the Data Sharing and Sample Testing Schedule or other mutually agreed timelines. Except to the extent otherwise agreed in a writing signed by authorized representatives of each Party, each Party shall use the other Party’s Sample Testing Results only for the purposes of ***. Further, Merck covenants not to ***, and Syndax covenants not ***; provided, however, that the foregoing shall not prevent either Party from ***. 3.7 All Clinical Data, including raw data and results, generated under this Agreement shall be jointly owned by Syndax and Merck. It is understood and acknowledged by the Parties that positive Clinical Data could be used to obtain label changes for the Compounds. In such event, the Parties will enter into good faith negotiations to determine a regulatory submission strategy for the Compounds, and cost structure of the next part of the Study and/or future study(ies) that may be needed for regulatory submission for the Compounds. Merck covenants not to ***, and Syndax covenants not to ***; provided, however, that the foregoing shall not prevent either Party from ***.

  • Project Description In two or three brief sentences, provide a concise description of your exhibition. Include the subject matter, type of objects to be included (paintings, sculpture, manuscripts, etc.), those responsible for organizing the exhibition, and catalogue author(s).

  • Description of the Services 1.1 The scope of the service to be rendered is described more fully in the Annexures and Schedules referred to below: ❑ Annexure A – Scope / Specification ❑ Annexure C – Pricing Schedule The Deliverables, due for completion by and governed by this Schedule 1. In the event that the Service Provider fails to meet the delivery dates as agreed, the following penalties will be imposed:

  • Scope of the Services UNOPS intends to retain the Contractor for the implementation of the Services, and the Contractor intends to provide the Services. The Contractor has represented to UNOPS that it has the appropriate experience, expertise, licences, and resources to undertake the Services and has agreed to undertake the Services in accordance with the Contract. In reliance on the Contractor’s representations UNOPS has entered into the Contract. The Contract sets out the terms and conditions upon which the Contractor will undertake the Services.

  • Timeline Contractor must perform the Services and deliver the Deliverables according to the following timeline:

  • Procurement of the Site (i) The Authority Representative, the Contractor and Authority’s Engineer shall, within 10 (ten) days of the date of this Agreement, inspect the Site and prepare a detailed memorandum containing an inventory of the Site including the vacant and unencumbered land, buildings, structures, road works, trees and any other immovable property on or attached to the Site (hereinafter referred to as the “Handover Memorandum”). Subject to the provisions of Clause 8.2 (iii), the Handover Memorandum shall have appended thereto an appendix (the “Appendix”) specifying in reasonable detail those parts of the Site to which vacant access and Right of Way has not been given to the Contractor along with details of hindrances in the Construction Zone. For sake of clarity the Handover Memorandum shall clearly specify the parts of Site where work can be executed. Signing of the Handover Memorandum, in three counterparts (each of which shall constitute an original), by the authorized representatives of the Authority, Contractor and Authority’s Engineer shall be deemed to constitute a valid evidence of giving the Right of Way to the Contractor for discharging its obligations under and in accordance with the provisions of this Agreement and for no other purpose whatsoever. (ii) Whenever the Authority is ready to hand over any part or parts of the Site included in the Appendix, it shall inform the Contractor, by notice, of the proposed date and time such of hand over. The Authority Representative and the Contractor shall, on the date so notified, inspect the specified parts of the Site, and prepare a memorandum containing an inventory of the vacant and unencumbered land, buildings, structures, road works, trees and any other immovable property on or attached to the Site so handed over. The signing of the memorandum, in three (3) counterparts (each of which shall constitute an original), by the authorised representatives of the Parties shall be deemed to constitute a valid evidence of giving the relevant Right of Way to the Contractor. If the contractor fails to join for site inspection or disputes the parts of the site available for work, the Authority’s Engineer shall decide the parts of the site where work can be executed and notify to both the parties within 3 days of the proposed date of inspection. The parties agree that such notification of the Authority’s Engineer as mentioned hereinabove shall be final and binding on the parties. (iii) The Authority shall provide the Right of Way to the Contractor in respect of all land included in the Appendix by the date specified in Schedule-A for those parts of the Site referred to therein, and in the event of delay for any reason other than Force Majeure or breach of this Agreement by the Contractor, it shall pay to the Contractor, Damages in a sum calculated in accordance with Clause 8.3. The Contractor agrees that it shall not be entitled to claim any other damages on account of any such delay by the Authority. (iv) Notwithstanding anything to the contrary contained in this Clause 8.2, the Authority shall specify the parts of the Site, if any, for which Right of Way shall be provided to the Contractor on the dates specified in Schedule-A. Such parts shall also be included in the Appendix prepared in pursuance of Clause 8.2 (i). (v) The Authority further acknowledges and agrees that prior to the Appointed Date, it shall have procured issuance of the statutory notification under Applicable Laws for vesting of all the land comprising the Project in the Authority and has taken possession of area for Construction Zone for at least 90% (ninety per cent) of the total length of the Project Highway. The Parties also acknowledge and agree that the conditions specified in this Clause 8.2 (iii) shall not be modified or waived by either Party. (vi) For the avoidance of doubt, the Parties expressly agree that the Appendix shall in no event contain sections of the Project Highway the cumulative length of which exceeds 10% (ten percent) of the total length of the Project Highway. (vii) Pursuant to signing of Handover Memorandum under clause 8.2 (i), Contractor shall submit to the Authority’s Engineer, a monthly land possession report till expiry of 180 (one hundred and eighty) days from Appointed Date, in respect of those parts of the site to which vacant access and right of way was not given to the contractor and included in Appendix to the memorandum signed under clause 8.2 (i), duly specifying the part of the site, if any, for which the right of way is yet to be handed over.

  • of the Standard Terms The Company hereby represents and warrants to the Trustee for the benefit of Certificateholders that as of the Closing Date (or, if otherwise specified below, as of the date so specified):

  • Budget Summary Other Sources (Page BudgetSum 2-3 - Acct 7000), must equal Other Uses (BudgetSum 2-3 - Acct. 8000). Estimated Beginning Fund Balance July,1 2020 for all Funds (Cells C3 - K3) (Line must have a number or zero. Do not leave blank.) OK Estimated Activity Fund Beginning Fund Balance July,1 2020 (Cell C83) (Cell must have a number or zero. Do not leave blank.) OK Transfer Among Funds (Funds 10, 20, 40 - Acct 7130 - Cells C29, D29, F29), must equal (Funds 10, 20 & 40 - Acct 8130 - Cells C52, D52, F52). OK Transfer of Interest (Funds 10 thru 90 - Acct 7140 - Cells C30:K30), must equal (Funds 10 thru 60, & 80 - Acct 8140 - Cells C53:H53, J53). OK Transfer to Debt Service to Pay Principal on Capital Leases (Fund 30 - Acct 7400 - Cell E39) must equal (Funds 10, 20 & 60 - Acct 8400 Cells C57:H60). OK Transfer to Debt Service to Pay Interest on Capital Leases (Fund 30 - Acct 7500 - Cell E40) must equal (Funds 10, 20 & 60 - Acct 8500 - Cells C61:H64). OK Transfer to Debt Service Fund to Pay Principal on Revenue Bonds (Fund 30 - Acct 7600 - Cell E41) must equal (Funds 10 & 20 - Acct 8600 - Cells C65:D68). OK Transfer to Debt Service to Pay Interest on Revenue Bonds (Fund 30 - Acct 7700 - Cell E42) must equal (Funds 10 & 20 - Acct 8700 - Cells C69:D72). OK Transfer to Capital Projects Fund (Fund 60 - Acct 7800 - Cell H43) must equal (Fund 10 & 20, Acct 8800 - Cells C73:D76). OK

  • Commercialization Plan (a) Not later than three [***] after submission of Regulatory Filings for each Product in each country of the Territory, Licensee will provide to the JCC for review its initial Commercialization Plan for each Product for each country in the Territory. Such initial Commercialization Plan will describe Licensee’s plans for activities to be conducted for such Product for such country. Each Commercialization Plan shall include the details of obligations to be performed by Licensee to achieve the specific activities that are applicable to the stage of [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Commercialization (e.g., pre-launch, launch planning, launch, or post-launch) of the applicable Product during the time period covered by such Commercialization Plan and subsequent time periods. (b) Prior to the First Commercial Sale for such Product in such country, Licensee will provide to the JCC for review an updated Commercialization Plan for such Product for such country. Such updated Commercialization Plan will include, but not be limited to, Licensee’s updated plans for activities to be conducted for such Product for such country prior to launch as well as activities to be conducted in connection with such launch. (c) Promptly after each anniversary of the First Commercial Sale of such Product during the Term, Licensee will provide to the JCC for review updated Commercialization Plans for such Product for such country. Such further updated Commercialization Plan will include, but not be limited to, Licensee’s plans for Commercialization activities for such Product and such country for the twelve (12) month period following the date of delivery of such Commercialization Plan. No Commercialization Plan may be implemented by Licensee if [***]. Each Commercialization Plan shall be consistent with and shall not contradict the terms of this Agreement [***], and in the event of any inconsistency between the Commercialization Plan and this Agreement, the terms of this Agreement shall prevail. Notwithstanding the foregoing, if a [***], Licensee shall [***] and shall promptly [***].

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!